We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MicroRNAs Linked to Neurodegenerative Disease

By Biotechdaily staff writers
Posted on 22 May 2002
Results from the study of a novel protein complex may help shed light on the function of a newly discovered class of small RNAs. More...
These "microRNAs” have been implicated in the development of spinal muscular atrophy, a hereditary neurodegenerative disease that is the second most common childhood neuromuscular disorder.

An international research group headed by Dr. Gideon Dreyfuss at the University of Pennsylvania School of Medicine (Philadelphia, USA) has identified 31 novel microRNAs (miRNAs), and the protein complex that houses them. Lately, miRNAs have received considerable attention, as they demonstrate widespread evolutionary distribution and are similar to other classes of small RNAs (approximately 22 nucleotides long) that are critical components of RNA interference and developmental gene regulation. So far, no function has been attributed to any of the miRNAs.

RNA transcripts do not exist as free molecules in the cell nucleus. Rather, RNAs exist in human cells as part of large ribonucleoprotein particles (RNPs) that contain various proteins. Dr. Dreyfuss and his colleagues found that the main protein components of the miRNPs are a eukaryotic translation initiation factor (eIF2C2) and previously identified components of the survival of motor neurons (SMN) complex, Gemin3 and Gemin4.

The presence of eIF2C2, an argonaute protein family member, in miRNPs confirms existing data implicating argonaute proteins in small RNA function. The presence of Gemin3 and 4, though, was a bit more surprising. The SMN complex is named for one of its main constituents, the survival of motor neurons protein, which, when mutated, results in spinal muscular atrophy. This finding of shared components between the SMN complex and the miRNP suggests a possible link between the pathway of miRNA activity and the progression of this disease.


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.